Close Menu

miRNA

The company also reported its financial results for 2009, posting a slight increase in its net loss for the year, which included the impact of operations from its now-discontinued Oncotech unit.

The newest deal will focus on miRNA-122, with hepatitis C infection as the initial indication.

IP Update: Feb 25, 2010

Premium

USPTO Publishes Four Patents, Five Patent Applications Related to RNAi

Researchers from Rosetta Genomics, in collaboration with investigators from NYU Langone Medical Center, this week published data in Cancer Research demonstrating that the microRNA could be used as a prognostic biomarker in patients with mesothelioma.

IP Update: Feb 18, 2010

Premium

USPTO Publishes Four Patents, Nine Patent Applications Related to RNAi

Concurrent with the move, the new company has also secured an undisclosed amount of seed financing that is expected to enable the new firm to complete planned in vivo proof-of-concept studies.

The test is expected to be available through Asuragen's clinical laboratory improvement amendments-certified lab in the second half of this year.

Papers of Note: Feb 4, 2010

Premium

RNAi- and microRNA-Related Papers Published January 2010

IP Update: Feb 4, 2010

Premium

USPTO Publishes Three Patents, Six Patent Applications Related to RNAi

People in the News: Feb 4, 2010

Premium

Palle Schelde, Thorlief Moller, John Riis Mortensen, Finn Cilius Nielsen, Ole Bitsch-Jensen, Daniel Kisner, Michael Forrest, Frank Karbe, Kenneth Galbraith, John Chiplin

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.